Neurogene Inc. Depreciation
Neurogene Inc. (NGNE) reported Depreciation of $1.40 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-20.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2023-03-20
- Neurogene Inc. depreciation for fiscal 2022 was $1.40M, a 27.27% increase from fiscal 2021.
- Neurogene Inc. depreciation for fiscal 2021 was $1.10M, a 83.33% increase from fiscal 2020.
- Neurogene Inc. depreciation for fiscal 2020 was $600.00K, a 200.00% increase from fiscal 2019.
- Neurogene Inc. depreciation for fiscal 2019 was $200.00K, a 33.33% decline from fiscal 2018.
| Period end | Depreciation 12 month |
|---|---|
| 2022-12-31 | $1.40M 10-K · filed 2023-03-20 |
| 2021-12-31 | $1.10M 10-K · filed 2023-03-20 |
| 2020-12-31 | $600.00K 10-K · filed 2022-03-01 |
| 2019-12-31 | $200.00K 10-K · filed 2021-03-25 |
| 2018-12-31 | $300.00K 10-K · filed 2020-03-12 |
| 2017-12-31 | $400.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |